Edaravone in Digestive Diseases - A Narrative Review.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-06-12 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S522011

Haiyun Lei, Mingchun Wang, Ma Huang, Xiaoyun Fu

{"title":"Edaravone in Digestive Diseases - A Narrative Review.","authors":"Haiyun Lei, Mingchun Wang, Ma Huang, Xiaoyun Fu","doi":"10.2147/DDDT.S522011","DOIUrl":null,"url":null,"abstract":"<p><p>Digestive diseases represent a diverse and complex group of systemic disorders, often marked by intricate pathogenic mechanisms and substantial rates of morbidity, disability, and mortality. While effective therapies exist for certain conditions, such as peptic ulcers, gastrointestinal hemorrhage, and viral hepatitis, many others remain difficult to manage due to their limited treatment options, poor response to current therapies, and multifactorial etiologies. As a result, there is a pressing need to develop novel therapeutic agents that offer greater specificity and improved clinical outcomes. Edaravone, a free radical scavenger widely used in the management of neurological disorders, has demonstrated a favorable safety profile and minimal adverse effects. Recent research has expanded our understanding of Edaravone's pharmacological actions, revealing its broad therapeutic potential beyond the nervous system. Its capacity to neutralize reactive oxygen species, reduce oxidative stress, suppress inflammation, inhibit apoptosis, modulate immune function, and enhance tissue repair positions it as a promising candidate for treating digestive disorders. This review highlights current advances in the application of Edaravone in digestive disease models and clinical settings, to offer new perspectives for future prevention, therapeutic strategies, and scientific investigation in this field.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5071-5084"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170441/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S522011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Digestive diseases represent a diverse and complex group of systemic disorders, often marked by intricate pathogenic mechanisms and substantial rates of morbidity, disability, and mortality. While effective therapies exist for certain conditions, such as peptic ulcers, gastrointestinal hemorrhage, and viral hepatitis, many others remain difficult to manage due to their limited treatment options, poor response to current therapies, and multifactorial etiologies. As a result, there is a pressing need to develop novel therapeutic agents that offer greater specificity and improved clinical outcomes. Edaravone, a free radical scavenger widely used in the management of neurological disorders, has demonstrated a favorable safety profile and minimal adverse effects. Recent research has expanded our understanding of Edaravone's pharmacological actions, revealing its broad therapeutic potential beyond the nervous system. Its capacity to neutralize reactive oxygen species, reduce oxidative stress, suppress inflammation, inhibit apoptosis, modulate immune function, and enhance tissue repair positions it as a promising candidate for treating digestive disorders. This review highlights current advances in the application of Edaravone in digestive disease models and clinical settings, to offer new perspectives for future prevention, therapeutic strategies, and scientific investigation in this field.

查看原文本刊更多论文

依达拉奉在消化系统疾病中的应用综述

消化系统疾病是一组多样而复杂的全身性疾病，通常具有复杂的致病机制和高发病率、致残率和死亡率。虽然对某些疾病有有效的治疗方法，如消化性溃疡、胃肠道出血和病毒性肝炎，但由于治疗选择有限、对现有疗法反应不佳以及多因素病因，许多其他疾病仍然难以控制。因此，迫切需要开发新的治疗药物，以提供更大的特异性和改善临床结果。依达拉奉是一种自由基清除剂，广泛用于神经系统疾病的治疗，具有良好的安全性和最小的不良反应。最近的研究扩大了我们对依达拉奉药理作用的了解，揭示了其在神经系统之外的广泛治疗潜力。它能够中和活性氧，减少氧化应激，抑制炎症，抑制细胞凋亡，调节免疫功能，增强组织修复，使其成为治疗消化系统疾病的有希望的候选者。本文综述了依达拉奉在消化系统疾病模型和临床应用方面的最新进展，为今后该领域的预防、治疗策略和科学研究提供新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.